LSP leads €11m Series A round in OneProject

The financing was led by LSP with Atlantic Bridge University Fund (Ireland) as co-investor, Enterprise Ireland and a selection of prominent contributing MedTech entrepreneurs. OneProjects Ltd is developing a novel technology in the field of medical imaging called VERAFEYE. The initial focus for OneProjects is to facilitate the treatment of cardiac arrhythmias such as atrial fibrillation. The funding will be used to advance product development, carry out clinical trials and prepare for US commercialisation of the system.

Atrial fibrillation (AFib) is an irregular heartbeat caused by chaotic electrical signals entering the heart and affects over 38 million people globally. One of the principal treatments for AFib is catheter ablation, which — despite technological advances — is only successful in about half of the procedures performed. By combining the use of advanced imaging and data analytics with its innovative catheter-based sensor system, VERAFEYE aims to increase the efficacy and safety of treatment for a growing number of patients worldwide.

As part of the transaction, Drew Burdon (Investment Manager at LSP) and Helen Ryan (Atlantic Bridge) joined the Board of Directors along with David Milne, previous managing partner at SV Healthcare Investors and former executive at Boston Scientific with over 30 years of experience in the healthcare industry.